{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050212","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.978633+00:00","generated_at":"2026-05-29T02:57:17.564436+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BriaPro reports Q1 net loss of $82K; cash at $1; going concern uncertainty","bullets":["Net loss $82,123 for three months to Oct 2024 vs $128,026 loss in prior year period.","Total assets $195,979; intangible assets (patents) net $195,978.","Current liabilities $522,835; shareholders' deficit $487,817; cash unchanged at $1.","Due to BriaCell (related party) $503,709; no revenue or commercial operations.","Going concern doubt due to pre-clinical stage and need for additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050212","json":"https://secwatch.observer/filing/0001493152-24-050212.json","markdown":"https://secwatch.observer/filing/0001493152-24-050212.md","text":"https://secwatch.observer/filing/0001493152-24-050212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224050212/0001493152-24-050212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224050212/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:57:17.564436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}